Synthesis and biological evaluation of 2,4-disubstituted phthalazinones as Aurora kinase inhibitors

Bioorg Med Chem. 2018 Jul 23;26(12):3217-3226. doi: 10.1016/j.bmc.2018.04.048. Epub 2018 Apr 23.

Abstract

A series of 2,4-disubstituted phthalazinones were synthesized and their biological activities, including antiproliferation, inhibition against Aurora kinases and cell cycle effects were evaluated. Among them, N-cyclohexyl-4-((4-(1-methyl-1H-pyrazol-4-yl)-1-oxophthalazin-2(1H)-yl) methyl) benzamide (12c) exhibited the most potent antiproliferation against five carcinoma cell lines (HeLa, A549, HepG2, LoVo and HCT116 cells) with IC50 values in range of 2.2-4.6 μM, while the IC50 value of reference compound VX-680 was 8.5-15.3 μM. Moreover, Aurora kinase assays exhibited that compound 12c was potent inhibitor of AurA and AurB kinase with the IC50 values were 118 ± 8.1 and 80 ± 4.2 nM, respectively. Molecular docking studies indicated that compound 12c forms better interaction with both AurA and AurB. Furthermore, compound 12c induced G2/M cell cycle arrest in HeLa cells by regulating protein levels of cyclinB1 and cdc2. These results suggested that 12c is a promising pan-Aurora kinase inhibitor for the potential treatment of cancer.

Keywords: Antitumor; Aurora kinase; Cell cycle; Phthalazinone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aurora Kinases / antagonists & inhibitors*
  • Aurora Kinases / metabolism
  • Binding Sites
  • CDC2 Protein Kinase / metabolism
  • Catalytic Domain
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cyclin B1 / metabolism
  • Down-Regulation / drug effects
  • Drug Design
  • Drug Screening Assays, Antitumor
  • G2 Phase Cell Cycle Checkpoints / drug effects
  • HCT116 Cells
  • HeLa Cells
  • Humans
  • Inhibitory Concentration 50
  • Molecular Docking Simulation
  • Phosphorylation / drug effects
  • Phthalazines / chemistry*
  • Phthalazines / metabolism
  • Phthalazines / pharmacology
  • Protein Kinase Inhibitors / chemical synthesis*
  • Protein Kinase Inhibitors / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Structure-Activity Relationship

Substances

  • Cyclin B1
  • Phthalazines
  • Protein Kinase Inhibitors
  • Aurora Kinases
  • CDC2 Protein Kinase